SCHEMBL7867799

SCHEMBL7867799

Cc1nc2cc(-c3ccc4c(c3)CN(C(=O)c3ccc5c(c3)OCO5)CCC4)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.51
HPGD P15428 9/20 0.50
ALDH1A1 P00352 7/20 0.50
NPC1 O15118 3/20 0.50
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ABCB1 P08183 1/20 0.47
CYP3A4 P08684 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
HSD17B10 Q99714 1/20 0.46
TSHR P16473 3/20 0.44
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 3/20 0.42
RAB9A P51151 2/20 0.41
RECQL P46063 2/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3747300 0.88 PIK3CA (0.65) PIK3CAHPGDALDH1A1NPC1TP53
SCHEMBL7868232 0.87 PIK3CA (0.47) PIK3CAHPGDALDH1A1NPC1TP53
SCHEMBL7864958 0.86 PIK3CA (0.49) PIK3CAALDH1A1ABCB1MAPTPKM
SCHEMBL7868233 0.85 PIK3CA (0.45) PIK3CAHPGDNPC1ABCB1TSHR
SCHEMBL7868242 0.85 PIK3CA (0.47) PIK3CAABCB1PKMKDM4E
SCHEMBL7870080 0.85 GPR142 (0.47) PIK3CAHPGDABCB1PKM
SCHEMBL7866569 0.84 GHSR (0.48) PIK3CAALDH1A1KDM4E
SCHEMBL7860217 0.84 PIK3CA (0.44) PIK3CAHPGDABCB1PKMKDM4E
SCHEMBL7864356 0.83 PKM (0.47) PIK3CAABCB1PKMMEN1KMT2A
SCHEMBL7867714 0.83 PIK3CA (0.47) PIK3CAHPGDABCB1CYP2C9PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR PIK3CA 16/4885HPGD 1748/4885ALDH1A1 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.